Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Operating Leases (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Operating Leases data on record, last reported at $60.0 million in Q4 2025.

  • For Q4 2025, Operating Leases changed 0.0% year-over-year to $60.0 million; the TTM value through Dec 2025 reached $60.0 million, changed 0.0%, while the annual FY2025 figure was $60.0 million, 0.0% changed from the prior year.
  • Operating Leases reached $60.0 million in Q4 2025 per CCCC's latest filing, up from $55.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $76.8 million in Q3 2022 and bottomed at $10.9 million in Q3 2021.
  • Average Operating Leases over 5 years is $55.6 million, with a median of $62.2 million recorded in 2024.
  • Peak YoY movement for Operating Leases: surged 602.87% in 2022, then dropped 12.58% in 2023.
  • A 5-year view of Operating Leases shows it stood at $30.8 million in 2021, then skyrocketed by 130.59% to $71.0 million in 2022, then fell by 7.35% to $65.8 million in 2023, then fell by 8.78% to $60.0 million in 2024, then changed by 0.0% to $60.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $60.0 million in Q4 2025, $55.2 million in Q3 2025, and $56.9 million in Q2 2025.